Table 1. Clinical characteristics of 10 control subjects and 10 HHD patients.
| Variables | Control patients n = 10 | HHD patients n = 10 | P value |
|---|---|---|---|
| Age (years old) | 61 ± 8 | 58 ± 12 | ns |
| Male / Female | 6 / 4 | 7 / 3 | ns |
| BMI (kg/m2) | 23.7 ± 1.9 | 26.1 ± 5.9 | ns |
| Hypertension, n (%) | 3 (30) | 10 (100) | <0.05 |
| Diabetes mellitus, n (%) | 1 (10) | 6 (60) | <0.05 |
| Dyslipidemia, n (%) | 3 (30) | 4 (40) | ns |
| NYHA functional class III-IV, n (%) | 0 (0) | 4 (40) | <0.05 |
| Echocardiographic data | |||
| LVEDD (mm) | 47 ± 5 | 55 ± 9 | <0.05 |
| LVEF (%) | 68 ± 6 | 52 ± 14 | <0.05 |
| IVSD (mm) | 9 ± 2 | 14 ± 2 | <0.05 |
| LVPWD (mm) | 10 ± 1 | 13 ± 2 | <0.05 |
| Blood examination | |||
| eGFR (mL/min/1.73 m2) | 92.0 ± 18.9 | 56.3 ± 25.5 | <0.05 |
| BNP (pg/mL) | 36 (17–70) | 463 (143–713) | <0.05 |
| Medications | |||
| ACEIs and/or ARBs, n (%) | 3 (30) | 10 (100) | <0.05 |
| CCBs, n (%) | 1 (10) | 7 (70) | <0.05 |
| Diuretics, n (%) | 0 (0) | 6 (60) | <0.05 |
| Statins, n (%) | 3 (30) | 5 (50) | ns |
Data are expressed as mean ± SD, number (percentage), or median (interquartile range).
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; BMI, body mass index; BNP, B-type natriuretic peptide; CCBs, calcium-channel blockers; eGFR, estimated glomerular filtration rate; HHD, hypertensive heart disease; IVSD, interventricular septum diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVPWD, left ventricular posterior wall diameter; NYHA, New York Heart Association.